Jyoti D. Patel, MD
Immunotherapy combination regimens continue to generate excitement as a treatment approach for patients with non–small cell lung cancer (NSCLC), as they may induce higher and more durable responses.
on Advanced Non–Small Cell Lung Cancer, Patel, professor of medicine, director of thoracic oncology, the University of Chicago Medicine, discussed ongoing research investigating immunotherapy in combination with chemotherapy for patients with NSCLC.
OncLive: Can you discuss your presentation on combination trials with immunotherapy in patients with lung cancer?
We have seen dramatic responses in subsets of patients with checkpoint blockade, particularly with the PD-1/PD-L1 axis. However, only about 20% of patients achieve responses. Efforts are now looking at how to bring this therapy to a broader subset of patients. We need to understand whether we can use dual-checkpoint inhibition to improve outcomes for tumors that may not be inflamed. [We also need to] better understand how to add immunotherapy to chemotherapy to give a greater number of patients a chance at response.
What are some combination strategies that you find particularly interesting?
The idea of upfront treatment with chemotherapy plus immunotherapy has been exciting. There is a scientific basis for this, as we see increased toxicity and neoantigen presentation. This is an area that people have been following since the inception of PD-1 blockade.
... to read the full story